Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm Study of the Safety and Antiretroviral Activity of Two Long-acting Broadly Neutralizing Antibodies Plus an IL-15 Superagonist in ART-treated Adults Living With HIV During Analytical Treatment Interruption

NCT05245292 is registered in ClinicalTrials.gov with Rockefeller University as lead sponsor.

NCT NCT05245292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm Study of the Safety and Antiretroviral Activity of Two Long-acting Broadly Neutralizing Antibodies Plus an IL-15 Superagonist in ART-treated Adults Living With HIV During Analytical Treatment Interruption
Lead sponsor
Rockefeller University
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2022
Completion date
December 31, 2025
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus